Vbi Vaccines (NASDAQ: VBIV)
Some price data may be temporarily unavailable.
Vbi Vaccines Return vs. S&P
| 1 Year | 5 Year | 5 Year Annualized | Since IPO |
|---|
Vbi Vaccines Company Info
VBI Vaccines, Inc. is a biopharmaceutical company, which engages in the development of infectious disease and immuno-oncology vaccines. The firm focuses on the prevention and treatment of hepatitis B through its product pipeline, Sci-B-Vac and VBI-2601. It also develops an enveloped virus-like particle (eVLP) platform technology, which allows the development of eVLP vaccines that closely mimic the target virus to elicit a potent immune response. The company was founded on April 9, 1965 and is headquartered in Cambridge, MA.
News & Analysis
Why Shares of VBI Vaccines Soared, and Then Fell 7%, on Tuesday
Investors almost seemed ready to take profits once shares hit their highest level since February.
Why VBI Vaccines Stock Is Vaulting Higher Today
The company reported good news from a study of its hepatitis B vaccine.
3 Top Healthcare Stocks Under $5
"Buy low, sell high" is easy when stocks are cheap. The hard part is finding inexpensive healthcare stocks that are more than just speculative trades.
Beware of Investing in These 3 Small-Cap Coronavirus Stocks
Here's why investors should stay away from some of the riskiest coronavirus stocks on the market.
Better Coronavirus Stock: Inovio Pharmaceuticals or VBI Vaccines?
Neither biotech is in the front of the pack in developing a COVID-19 vaccine.
Why These Coronavirus Vaccine Stocks Crashed in September
In the race for a vaccine, a pause in progress sets you back.
Why VBI Vaccines Stock Jumped Today
The biotech will present additional data for one of its pipeline candidates later this week.
Why Is Everyone Talking About VBI Vaccines Stock?
Investors who are looking for promising coronavirus vaccine stocks should keep an eye out for this emerging biotech.
Valuation
Related Stocks
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.